ESR2, estrogen receptor 2, 2100

N. diseases: 528; N. variants: 56
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C1458155
Disease: Mammary Neoplasms
Mammary Neoplasms
0.400 Biomarker group BEFREE This review addresses the signaling of ERβ and GPER in ERα-negative breast tumors. 30687231 2018
CUI: C1458155
Disease: Mammary Neoplasms
Mammary Neoplasms
0.400 AlteredExpression group BEFREE The establishment of a clear association is required; therefore, the current study analyzed the expression patterns of ERα and ERβ in 32 breast tumor tissues using reverse transcription-quantitative polymerase chain reaction. 28808484 2017
CUI: C1458155
Disease: Mammary Neoplasms
Mammary Neoplasms
0.400 AlteredExpression group BEFREE The human ERβ variant ERβ2 is proposed to be expressed at higher levels than ERβ1 in many breast tumors and it has been suggested that ERβ2, in contrast to ERβ1, is associated with aggressive phenotypes of various cancers. 29100336 2017
CUI: C1458155
Disease: Mammary Neoplasms
Mammary Neoplasms
0.400 AlteredExpression group BEFREE Upregulation of estrogen receptor beta (ERβ) in breast cancer cells is associated with epithelial maintenance, decreased proliferation and invasion, and a reduction in the expression of the receptor has been observed in invasive breast tumors. 28673316 2017
CUI: C1458155
Disease: Mammary Neoplasms
Mammary Neoplasms
0.400 GeneticVariation group BEFREE However, when combined with MSI/LOH in AR, ERβ and CYP19 genes, we were able to detect significant associations with the GSTP1 wild-type genotype in PR (progesterone receptor) negative breast cancers or the CYP17 wild-type genotype in ER (estrogen receptor) and PR-negative breast tumors. 28692125 2017
CUI: C1458155
Disease: Mammary Neoplasms
Mammary Neoplasms
0.400 AlteredExpression group BEFREE The HYAL1 repression was also specific to ERα and not to ERβ, whose expression did not correlate with HYAL1 in human breast tumors. 27764788 2016
CUI: C1458155
Disease: Mammary Neoplasms
Mammary Neoplasms
0.400 AlteredExpression group BEFREE Obesity is associated with a worse breast cancer prognosis, while greater breast tumor estrogen receptor beta (ERβ) expression is correlated with improved therapy response and survival. 26709918 2015
CUI: C1458155
Disease: Mammary Neoplasms
Mammary Neoplasms
0.400 AlteredExpression group BEFREE While the proliferative role of ERα in breast tumors is well characterized, it is not clear whether the antitumor activity of ERβ can be mobilized in breast cancer cells. 24960160 2014
CUI: C1458155
Disease: Mammary Neoplasms
Mammary Neoplasms
0.400 AlteredExpression group BEFREE The second ER, ERβ, is also expressed in breast tumors, but its function and therapeutic potential need further study. 24192230 2014
CUI: C1458155
Disease: Mammary Neoplasms
Mammary Neoplasms
0.400 PosttranslationalModification group BEFREE In general, ERβ promoter methylation was found in 44.9% (80/178) of breast tumor samples, significantly higher than the benign breast hyperplasia (44.9% vs. 14.3%, X(2) = 4.986, P = 0.026). 22105146 2012
CUI: C1458155
Disease: Mammary Neoplasms
Mammary Neoplasms
0.400 Biomarker group BEFREE Our data demonstrate that PES1 contributes to breast tumor growth through regulating the balance between ERα and ERβ and may be a better target for the development of drugs that selectively regulate ERα and ERβ activities. 22820289 2012
CUI: C1458155
Disease: Mammary Neoplasms
Mammary Neoplasms
0.400 AlteredExpression group BEFREE Expression of ERβ in breast tumors has been implicated as an indicator of tamoxifen sensitivity. 21492444 2011
CUI: C1458155
Disease: Mammary Neoplasms
Mammary Neoplasms
0.400 Therapeutic group CTD_human Estrogen receptor beta exerts growth-inhibitory effects on human mammary epithelial cells. 19434490 2010
CUI: C1458155
Disease: Mammary Neoplasms
Mammary Neoplasms
0.400 Biomarker group CTD_human Estrogen receptor beta exerts growth-inhibitory effects on human mammary epithelial cells. 19434490 2010
CUI: C1458155
Disease: Mammary Neoplasms
Mammary Neoplasms
0.400 Therapeutic group CTD_human "c-erbB-2 and the ""triple-state"" in early breast carcinomas." 19548127 2010
CUI: C1458155
Disease: Mammary Neoplasms
Mammary Neoplasms
0.400 Biomarker group CTD_human "c-erbB-2 and the ""triple-state"" in early breast carcinomas." 19548127 2010
CUI: C1458155
Disease: Mammary Neoplasms
Mammary Neoplasms
0.400 Biomarker group LHGDN Clinical importance of estrogen receptor-beta evaluation in breast cancer patients treated with adjuvant tamoxifen therapy. 18669459 2008
CUI: C1458155
Disease: Mammary Neoplasms
Mammary Neoplasms
0.400 Biomarker group LHGDN Nuclear and cytoplasmic expression of ERbeta1, ERbeta2, and ERbeta5 identifies distinct prognostic outcome for breast cancer patients. 18698041 2008
CUI: C1458155
Disease: Mammary Neoplasms
Mammary Neoplasms
0.400 Biomarker group LHGDN Crosstalk between the estrogen receptor and the HER tyrosine kinase receptor family: molecular mechanism and clinical implications for endocrine therapy resistance. 18216219 2008
CUI: C1458155
Disease: Mammary Neoplasms
Mammary Neoplasms
0.400 GeneticVariation group LHGDN Association of repeat polymorphisms in the estrogen receptors alpha, beta (ESR1, ESR2) and androgen receptor (AR) genes with the occurrence of breast cancer. 17904846 2008
CUI: C1458155
Disease: Mammary Neoplasms
Mammary Neoplasms
0.400 Biomarker group LHGDN A novel gene STYK1/NOK is upregulated in estrogen receptor-alpha negative estrogen receptor-beta positive breast cancer cells following estrogen treatment. 17415682 2008
CUI: C1458155
Disease: Mammary Neoplasms
Mammary Neoplasms
0.400 AlteredExpression group LHGDN Evaluation of estrogen receptor alpha and beta and progesterone receptor expression and correlation with clinicopathologic factors and proliferative marker Ki-67 in breast cancers. 18234277 2008
CUI: C1458155
Disease: Mammary Neoplasms
Mammary Neoplasms
0.400 AlteredExpression group LHGDN Inhibitory effects of estrogen receptor beta on specific hormone-responsive gene expression and association with disease outcome in primary breast cancer. 17428314 2007
CUI: C1458155
Disease: Mammary Neoplasms
Mammary Neoplasms
0.400 Biomarker group LHGDN Estrogen receptor-beta: why may it influence clinical outcome in estrogen receptor-alpha positive breast cancer? 17617929 2007
CUI: C1458155
Disease: Mammary Neoplasms
Mammary Neoplasms
0.400 AlteredExpression group LHGDN The effect of chemotherapy on status of estrogen receptors in primary tumors and lymph node metastases of human ductal breast cancer. 17203178 2007